Expression of the polycomb-group gene BMI1 is related to an unfavourable prognosis in primary nodal DLBCL

Journal of Clinical Pathology

Volumn 60, Issue 2, 2007, Pages 167-172

  Van Galen, Joost C ^a   Muris, Jettie J F ^a   Oudejans, Joost J ^a   Vos, Wim ^a   Giroth, Cindy P E ^a   Ossenkoppele, Gert J ^a   Otte, Arie P ^b   Raaphorst, Frank M ^a,c   Meijer, Chris J L M ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c CRUCELL HOLLAND BV   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ARF PROTEIN; PROTEIN P14; PROTEIN P16INK4A;

ARTICLE; B CELL LYMPHOMA; BMI 1 GENE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; MALE; PHENOTYPE; PRIORITY JOURNAL; PROTO ONCOGENE;

ADULT; AGED; AGED, 80 AND OVER; CYCLIN-DEPENDENT KINASE INHIBITOR P16; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; LYMPHOCYTE ACTIVATION; LYMPHOMA, B-CELL; LYMPHOMA, LARGE-CELL, DIFFUSE; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NUCLEAR PROTEINS; PROGNOSIS; PROTO-ONCOGENE PROTEINS; REPRESSOR PROTEINS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P14ARF;

EID: 33846982558     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.2006.038752     Document Type: Article

References (32)

1. The International Non-Hodgkin's Lymphomas Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993;329:987-94.
2. Kramer MH, Hermans J, Parker J, et al. Clinical significance of Bcl-2 and p53 protein expression in diffuse large B-cell lymphoma: a population-based study. J Clin Oncol 1998;14:2131-8.
3. Barrens SL, Carter I, Owen RG, et al. Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma. Blood 2002;99:1136-43.
4. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004;103:275-82.
5. Lossos IS, Jones CD, Warnke R, et al. Expression of a single gene, BCL-6, strongly predicts survival in patients with diffuse large B-cell lymphoma. Blood 2001;98:945-51.
6. Chang CC, Liu YC, Cleveland RP, et al. Expression of c-Myc and p53 correlates with clinical outcome in diffuse large B-cell lymphomas. Am J Clin Pathol 2000;113:512-18.
7. Yamaguchi M, Seto M, Okamoto M, et al. De novo CD5+ diffuse large B-cell lymphoma: a clinicopathologic study of 109 patients. Blood 2002;99:815-21.
8. Muris JJ, Meijer O, Cillessen SA, et al. Prognostic significance of activated cytotoxic T-lymphocytes in primary nodal diffuse large B-cell lymphomas. Leukemia 2004;18:589-96.
9. Muris JJ, Cillessen SA, Vos W, et al. Immunohistochemical profiling of caspase signaling pathways predicts clinical response to chemotherapy in primary nodal diffuse large B-cell lymphomas. Blood 2005;105:2916-23.
10. Kuppers R, Klein U, Hansmann ML, et al. Cellular origin of human B-cell lymphomas. N Engl J Med 1999;341:1520-9.
11. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000;403:503-11.
12. Shipp MA, Ross KN, Tamayo P, et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 2002;8:68-74.
13. de Boer WP, Oudejans JJ, Meijer O, et al. Analysing gene expressions with GRANK. Bioinformatics 2003;19:2000-1.
14. Raaphorst FM, Otte AP, Meijer CJ. Polycomb-group genes as regulators of mammalian lymphopoiesis. Trends Immunol 2001;22:682-90.
15. Jacobs JJ, Kieboom K, Marino S, et al. The oncogene and Polycomb-group gene BMI1 regulates cell proliferation and senescence through the ink4a locus. Nature 1999;397:164-8.
16. van Lohuizen M, Verbeek S, Scheijen B, et al. Identification of cooperating oncogenes in E mu-myc transgenic mice by provirus tagging. Cell 1991;65:737-52.
17. Alkema MJ, Bronk M, Verhoeven E, et al. Identification of BMI1-interacting proteins as constituents of a multimeric mammalian polycomb complex. Genes Dev 1997;11:226-40.
18. Jacobs JJ, Scheijen B, Voncken JW, et al. BMI1 collaborates with c-Myc in tumorigenesis by inhibiting c-Myc-induced apoptosis via INK4a/ARF. Genes Dev 1999;13:2678-90.
19. Ruas M, Peters G. The p16INK4a/CDKN2A tumor suppressor and its relatives. Biochim Biophys Acta 1998;1378:F115-77.
20. Park IK, Morrison SJ, Clarke MF. Bmi1, stem cells, and senescence regulation. J Clin Invest 2004;113:175-9.
21. Lowe SW, Sherr a. Tumor suppression by Ink4a-Arf: progress and puzzles. Curr Opin Genet Dev 2003;13:77-83.
22. Van Galen JC, Dukers DF, Giroth C, et al. Distinct expression patterns of polycomb oncoproteins and their binding partners during the germinal center reaction. Eur J Immunol 2004;34:1870-81.
23. van Kemenade FJ, Raaphorst FM, Blokzijl T, et al. Coexpression of BMI1 and EZH2 polycomb-group proteins is associated with cycling cells and degree of malignancy in B-cell non-Hodgkin lymphoma. Blood 2001;97:3896-901.
24. Raophorst FM. Of mice, flies, and man: the emerging role of polycomb-group genes in human malignant lymphomas. Int J Hematol 2005;81:281-7.
25. Valk-Lingbeek ME, Bruggeman SW, van Lohuizen M. Stem cells and cancer; the polycomb connection. Cell 2004;118:409-18.
26. Hamer KM, Sewalt RG, den Blaauwen JL, et al. A panel of monoclonal antibodies against human polycomb group proteins. Hybrid Hybridomics 2002;21:245-52.
27. Muris JJF, Meijer CJLM, Vos W, et al. Immunohistochemical profiling based on Bcl-2, CD10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B-cell lymphoma. J Pathol 2006;208:714-23.
28. Cox DR. Regression models and life tables. J Roy Statist Soc Ser B Methodol 1972;34:187-220.
29. Raaphorst FM, van Kemenade FJ, Fieret E, et al. Cutting edge: polycomb gene expression patterns reflect distinct B cell differentiation stages in human germinal centers. J Immunol 2000;164:1-4.
30. Sanchez-Aguilera A, Sanchez-Beato M, Garcia JF, et al. p14(ARF) nuclear overexpression in aggressive B-cell lymphomas is a sensor of malfunction of the common tumor suppressor pathways. Blood 2002;99:1411-18.
31. Voneken JW, Niessen H, Neufeld B, et al. MAPKAP kinase 3pK phosphorylates and regulates chromatin association of the polycomb group protein Bmi 1. J Biol Chem 2005;280:5178-87.
32. Glinsky GV, Berezovska O, Glinskii AB. Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. J Clin Invest 2005;115:1503-21.